Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 16/20 | 0.69 |
| ▸ | PLK3 | Q9H4B4 | 10/20 | 0.69 |
| ▸ | NEK2 | P51955 | 3/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.67 |
| ▸ | PIM1 | P11309 | 2/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.67 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.67 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.67 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.67 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.67 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.67 |
| ▸ | STK10 | O94804 | 1/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.67 |
| ▸ | KIT | P10721 | 1/20 | 0.67 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.67 |
| ▸ | GRK4 | P32298 | 1/20 | 0.67 |
| ▸ | TIE1 | P35590 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.67 |
| ▸ | PRKCI | P41743 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265222 | 1.00 | PLK1 (0.69) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2990324 | 0.93 | PLK1 (0.68) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL13592906 | 0.93 | PLK1 (0.68) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2984691 | 0.92 | PLK1 (0.67) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2988855 | 0.92 | PLK1 (0.70) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2983841 | 0.91 | PLK1 (0.65) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL4403613 | 0.91 | PLK1 (0.65) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL4404894 | 0.91 | PLK1 (0.63) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL14029566 | 0.90 | PLK1 (0.65) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2983028 | 0.90 | PLK1 (0.64) | PLK1PLK3NEK2PIK3CDPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| EP-2032563-B1 | BENZIMIDAZOL SUBSTITUTED THIOPHENE DERIVATIVES WITH ACTIVITY ON PLK | GLAXOSMITHKLINE LLC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| EP-1924572-B1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1924572-B1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1937671-B1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| EP-1937671-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SmithKline Beecham Corporation (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1924572-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SmithKline Beecham Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| WO-2007030366-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030366-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030361-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030361-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | ABCB1, ABCG2, CYP3A5 | PLK1 344/4885PLK3 934/4885NEK2 2296/4885 |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | PLK1 458/4885PLK3 1235/4885NEK2 2703/4885 |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | ABCB1, CYP3A5, CYP3A4 | PLK1 450/4885PLK3 1025/4885NEK2 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.